Effect of Dapagliflozin on Inflammation and Endothelial Function
Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce hyperglycemia and improve
peripheral insulin sensitivity by ameliorating glucotoxicity. Insulin resistance in type 2
diabetes (T2DM) is associated with endothelial dysfunction and vascular inflammation. Thus
strategies to improve insulin sensitivity and lower glucotoxicity may improve endothelial
inflammation and vascular inflammation. However, the effects of these agents on vascular
inflammation and endothelial function is not known in patients with type 2 diabetes although
anti-inflammatory properties have been demonstrated in various animal models. In the present
study the investigators will assess if dapagliflozin treatment for 12 weeks decreases
monocyte inflammation and improves endothelial function in patients with type 2 diabetes on
metformin monotherapy.